L.a.n.c.e. Chemosensitivity testing at the highest level· Laboratory for Applied Neoplasia Research and Cytostatics Evaluation

Literatur Zum ATP-TCA liegen zahlreiche wissenschaftliche Studienergebnisse vor. Vor allem die klinischen Studien belegen die hohe prädiktive Aussagefähigkeit des Verfahrens, das sich nicht nur bei der individuellen Therapieplanung, sondern auch in der Entwicklung innovativer Therapieregime bereits hervorragend bewährt hat.

International Literature
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Feasibility of chemosensitivity testing in soft tissue sarcomas.
Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.
In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Chemosensitivity testing in malignant melanoma.
Chemosensitivity testing in gynecologic oncology–dream or reality?

Staib P, Staltmeier E, Neurohr K, Cornely O, Reiser M, Schinkothe T.
Br J Haematol. 2005 Mar;128(6):783-91.

Clinic I for Internal Medicine, University of Cologne, D-50924 Cologne, Germany.

As the response to chemotherapy in patients with acute myeloid leukaemia (AML) may still not be accurately determined by known prognostic factors, such as karyotype, the ex vivo chemosensitivity profile may help to predict the individual response. The predictive accuracy of an ex vivo assay should be assessed by correlation of assay results with both response rate and survival. We prospectively investigated the prognostic relevance of pre-therapeutic ex vivo chemosensitivity testing in primary cell cultures from adult AML patients by applying a new evaluation methodology, designated the chemosensitivity index, C(i). This C(i) was designed as a prognostic index by taking the area under the curve as an exact measure of the total dose-response relationship. We found an overall predictive accuracy of 98.2% concerning treatment response, which compares favourably with previously published data ranging from 75% to 92%. Moreover, the C(i) proved to be the strongest prognostic factor for overall survival in a multivariate Cox regression analysis including karyotype grouping and age (P < 0.001), and enabled the evaluation of response to combination therapies and selection of possible treatment alternatives. Our data suggest that ex vivo chemosensitivity testing evaluated by the C(i) could serve as a powerful tool for assay-directed therapy strategies in AML.
Publication Types:
* Clinical Trial
* Clinical Trial, Phase II
* Randomized Controlled Trial